New types of collaborations and clinical trials reshaping research & development

The rapid development of novel vaccines for COVID-19 demonstrates that a new type of streamlining and efficiency is indeed possible.

Clinical trials
COVID-19 vaccine development

Industry mean average for new drug development and review prior to COVID-19 = 8.2 years

Changes to drug development brought on by COVID-19:
- Exposing long-standing inefficiencies
- Reassessing processes and challenging steps previously thought to be necessary and fundamental
- Fostering new collaborations within and beyond the health care ecosystem

Regulators are becoming more flexible about clinical trial design and the speed at which trials are conducted

Virtual trials and remote monitoring enable greater patient involvement and give patients an active voice in research

Need to address diversity and inclusion in clinical trials

Decentralized clinical trials are executed at the point of care through telemedicine and mobile and local health care providers

More trials will be hybrid trials going forward, a combination of in-person and virtual visits

Beyond vaccines, oncology is expected to continue to be a major driver of the sector’s top line growth. It accounts for 6 out of the 10 biggest new sales generators and 4 of the top ten best-selling products.

Collaborations across the whole ecosystem will continue to be key:

Data will be key in the shift to transformative drug development approaches:
- Real World Data
- Real World Evidence
- AI
- Cloud

Learn more at www.deloitte.com/lifesciencesoutlook

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see www.deloitte.com/about for a more detailed description of DTTL and its member firms. Deloitte provides audit, consulting, financial advisory, risk management, tax and related services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries and territories, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte’s more than 200,000 professionals are committed to becoming the standard of excellence.

Disclaimer
This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the “Deloitte Network”) is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this publication.

About Life Sciences and Health Care at Deloitte Touche Tohmatsu Limited
The Deloitte Touche Tohmatsu limited life sciences and health care industry group is composed of more than 12,000 professionals in more than 90 countries. These member firm professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, clients’ professionals work across the Deloitte network to companies to evolve in a changing marketplace, pursue new and innovative solutions, and maximize their profitability.

For more information about the DTTL, G&H, Industry group, email dlhhc@deloitte.com or access www.deloitte.com/lifesciences.

©2021. For more information, contact Deloitte Touche Tohmatsu limited.